dc.contributor.author | Koen, Yakov M. | |
dc.contributor.author | Hajovsky, Heather | |
dc.contributor.author | Liu, Ke | |
dc.contributor.author | Williams, Todd D. | |
dc.contributor.author | Galeva, Nadezhda A. | |
dc.contributor.author | Staudinger, Jeffrey Leonard | |
dc.contributor.author | Hanzlik, Robert P. | |
dc.date.accessioned | 2017-05-08T16:29:47Z | |
dc.date.available | 2017-05-08T16:29:47Z | |
dc.date.issued | 2012-08-20 | |
dc.identifier.citation | Koen, Y. M., Hajovsky, H., Liu, K., Williams, T. D., Galeva, N. A., Staudinger, J. L., & Hanzlik, R. P. (2012). Liver Protein Targets of Hepatotoxic 4-Bromophenol Metabolites. Chemical Research in Toxicology, 25(8), 1777–1786. http://doi.org/10.1021/tx3002675 | en_US |
dc.identifier.uri | http://hdl.handle.net/1808/24002 | |
dc.description | This document is the Accepted Manuscript version of a Published Work that appeared in final form in
Chemical Research in Toxicology, copyright © American Chemical Society after peer review and technical editing by the publisher.
To access the final edited and published work see http://pubs.acs.org/doi/abs/10.1021/tx3002675 | en_US |
dc.description.abstract | The hepatotoxicity of bromobenzene (BB) is directly related to the covalent binding of both initially formed epoxide and secondary quinone metabolites to at least 45 different liver proteins. 4-Bromophenol (4BP) is a significant BB metabolite and a precursor to reactive quinone metabolites, yet when administered exogenously it has negligible hepatotoxicity compared to BB. The protein adducts of 4BP were thus labeled as non-toxic (Monks, T. J.; Hinson, J. A.; Gillette, J. R. (1982) Life Sci. 30, 841–848). To help identify which BB-derived adducts might be related to its cytotoxicity, we sought to identify the supposedly non-toxic adducts of 4BP and eliminate them from the BB target protein list. Administration of [14C]-4BP to phenobarbital-induced rats resulted in covalent binding of 0.25, 0.33 and 0.42 nmol-eq 4BP/mg protein in the mitochondrial, microsomal and cytosolic fractions, respectively. These values may be compared to published values of 3–6 nmol/mg protein from a comparable dose of [14C]-BB. After subcellular fractionation and 2D electrophoresis, 47 radioactive spots on 2D gels of the mitochondrial, microsomal and cytosolic fractions were excised, digested and analyzed by LC-MS/MS. Twenty nine of these spots contained apparently single proteins, of which 14 were non-redundant. Nine of the 14 are known BB targets. Incubating freshly-isolated rat hepatocytes with 4BP (0.1–0.5 mM) produced time- and concentration-dependent increases in lactate dehydrogenase release and changes in cellular morphology. LC-MS/MS analysis of the cell culture medium revealed rapid and extensive sulfation and glucuronidation of 4BP as well as formation of a quinone-derived glutathione conjugate. Studies with 7-hydroxycoumarin (7HC), (−)-borneol or D-(+)-galactosamine (DGN) showed that inhibiting the glucuronidation/sulfation of 4BP increased the formation of a GSH-bromoquinone adduct, increased covalent binding of 4BP to hepatocyte proteins and potentiated its cytotoxicity. Taken together, our data demonstrate that protein adduction by 4BP metabolites can be toxicologically consequential, and provide a mechanistic explanation for the failure of exogenously administered 4BP to cause hepatotoxicity. Thus the probable reason for the low toxicity of 4BP in vivo is that rapid conjugation limits its oxidation and covalent binding and thus its toxicity. | en_US |
dc.publisher | ACS | en_US |
dc.rights | © 2012 American Chemical Society | en_US |
dc.title | Liver Protein Targets of Hepatotoxic 4-Bromophenol Metabolites | en_US |
dc.type | Article | en_US |
kusw.kuauthor | Koen, Yakov M. | |
kusw.kuauthor | Hajovsky, Heather | |
kusw.kuauthor | Liu, Ke | |
kusw.kuauthor | Hanzlik, Robert P. | |
kusw.kuauthor | Williams, Todd D. | |
kusw.kuauthor | Galeva, Nadezhda A. | |
kusw.kuauthor | Staudinger, Jeffrey L. | |
kusw.kudepartment | Medicinal Chemistry | en_US |
kusw.kudepartment | Mass Spectrometry Laboratory | en_US |
kusw.kudepartment | Pharmacology & Toxicology | en_US |
kusw.oanotes | Per SherpaRomeo on 05/08/2017: Author's Pre-print: grey tick subject to Restrictions below, author can archive pre-print (ie pre-refereeing) Restrictions: Must obtain written permission from Editor Must not violate ACS ethical Guidelines Author's Post-print: grey tick subject to Restrictions below, author can archive post-print (ie final draft post-refereeing) Restrictions: If mandated by funding agency or employer/ institution If mandated to deposit before 12 months, must obtain waiver from Institution/Funding agency or use AuthorChoice 12 months embargo Publisher's Version/PDF: cross author cannot archive publisher's version/PDF
General Conditions: On author's personal website, pre-print servers, institutional website, institutional repositories or subject repositories Non-Commercial Must be accompanied by set statement (see policy) Must link to publisher version Publisher's version/PDF cannot be used | en_US |
dc.identifier.doi | 10.1021/tx3002675 | en_US |
kusw.oaversion | Scholarly/refereed, author accepted manuscript | en_US |
kusw.oapolicy | This item meets KU Open Access policy criteria. | en_US |
dc.identifier.pmid | PMC3431021 | en_US |
dc.rights.accessrights | openAccess | |